These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 10931445)

  • 1. Integration of cost-effective early detection programs into the health services of developing countries.
    Sankaranarayanan R
    Cancer; 2000 Aug; 89(3):475-81. PubMed ID: 10931445
    [No Abstract]   [Full Text] [Related]  

  • 2. De novo establishment and cost-effectiveness of Papanicolaou cytology screening services in the Socialist Republic of Vietnam.
    Suba EJ; Nguyen CH; Nguyen BD; Raab SS;
    Cancer; 2001 Mar; 91(5):928-39. PubMed ID: 11251944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Customizing anticancer strategies to local needs.
    Webb S
    J Natl Cancer Inst; 2009 Jun; 101(12):842-4. PubMed ID: 19509362
    [No Abstract]   [Full Text] [Related]  

  • 4. Use of modeling to evaluate the cost-effectiveness of cancer screening programs.
    Knudsen AB; McMahon PM; Gazelle GS
    J Clin Oncol; 2007 Jan; 25(2):203-8. PubMed ID: 17210941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Developing and testing a cost-assessment tool for cancer screening programs.
    Subramanian S; Ekwueme DU; Gardner JG; Trogdon J
    Am J Prev Med; 2009 Sep; 37(3):242-7. PubMed ID: 19666160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of health services: more than dollars saved.
    Stoddart GL
    CMAJ; 1987 Feb; 136(3):237-8. PubMed ID: 3100010
    [No Abstract]   [Full Text] [Related]  

  • 7. Examining the cost-effectiveness of cancer screening promotion.
    Andersen MR; Urban N; Ramsey S; Briss PA
    Cancer; 2004 Sep; 101(5 Suppl):1229-38. PubMed ID: 15316909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health and wealth.
    Nat Med; 2002 Feb; 8(2):89. PubMed ID: 11821872
    [No Abstract]   [Full Text] [Related]  

  • 9. Estimating production costs in the economic evaluation of health-care programs.
    Herrero C; Moreno-Ternero JD
    Health Econ; 2009 Jan; 18(1):21-35. PubMed ID: 18264993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. De novo establishment and cost-effectiveness of Papanicolaou cytology screening services in the Socialist Republic of Vietnam.
    Levin CE; Sellors JW
    Cancer; 2002 Apr; 94(8):2312-4; author reply 2314-6. PubMed ID: 12001136
    [No Abstract]   [Full Text] [Related]  

  • 11. [Cost effectiveness of human papilloma virus testing in cervical cancer screening: a literature review].
    Mejía A; Salas W
    Biomedica; 2008 Mar; 28(1):160-72. PubMed ID: 18645671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of mass screening programmes in health.
    Kayima JK
    East Afr Med J; 1997 Aug; 74(8):465-6. PubMed ID: 9487408
    [No Abstract]   [Full Text] [Related]  

  • 13. Poverty, development, and health policy.
    Abel-Smith B; Leiserson A
    Public Health Pap; 1978; (69):7-109. PubMed ID: 104440
    [No Abstract]   [Full Text] [Related]  

  • 14. The futility and lack of cost-effectiveness in screening for cancer.
    Handler S
    Minn Med; 1992 Dec; 75(12):13-6. PubMed ID: 1470083
    [No Abstract]   [Full Text] [Related]  

  • 15. Reproductive cancers: women's access to screening services.
    Arrows Change; 1997 Dec; 3(3):1-2. PubMed ID: 12294551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost benefits of cancer services.
    Rees G
    Health Serv J; 1986 Apr; 96(4994):490-1. PubMed ID: 10311551
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-benefit impact on cancer screening.
    Humphrey LJ
    Semin Surg Oncol; 1989; 5(3):205-10. PubMed ID: 2500695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Economic criteria in assessing the efficacy of the fight against cancer].
    Diatchenko OT; Shabashova NIa
    Vopr Onkol; 1988; 34(12):1411-21. PubMed ID: 3146159
    [No Abstract]   [Full Text] [Related]  

  • 19. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications.
    Goldie SJ; O'Shea M; Diaz M; Kim SY
    Reprod Health Matters; 2008 Nov; 16(32):86-96. PubMed ID: 19027626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medicine. The intangible value of vaccination.
    Rappuoli R; Miller HI; Falkow S
    Science; 2002 Aug; 297(5583):937-9. PubMed ID: 12169712
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.